Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.77 |
| ▸ | BLM | P54132 | 2/20 | 0.77 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.77 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.77 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.77 |
| ▸ | POLB | P06746 | 2/20 | 0.77 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.77 |
| ▸ | MAPT | P10636 | 2/20 | 0.77 |
| ▸ | HPGD | P15428 | 2/20 | 0.77 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.77 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.77 |
| ▸ | MEN1 | O00255 | 1/20 | 0.77 |
| ▸ | USP2 | O75604 | 1/20 | 0.77 |
| ▸ | EGFR | P00533 | 1/20 | 0.77 |
| ▸ | FYN | P06241 | 1/20 | 0.77 |
| ▸ | GAA | P10253 | 1/20 | 0.77 |
| ▸ | APEX1 | P27695 | 1/20 | 0.77 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.77 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.77 |
| ▸ | MTOR | P42345 | 1/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10608436 | 1.00 | TDP1 (0.77) | TDP1BLMKDM4EALDH1A1CYP1A2 | |
| SCHEMBL6338791 | 1.00 | TDP1 (0.77) | TDP1BLMKDM4EALDH1A1CYP1A2 | |
| Hydrochloric Acid SCHEMBL1578093 | 0.98 | TDP1 (0.74) | TDP1BLMKDM4EALDH1A1CYP1A2 | |
| SCHEMBL6716878 | 0.87 | TDP1 (0.58) | TDP1BLMKDM4EALDH1A1CYP1A2 | |
| Methyldopa SCHEMBL1321546 | 0.87 | KDM4E (1.00) | TDP1BLMKDM4EALDH1A1CYP1A2 | |
| Methyldopa SCHEMBL30176814 | 0.87 | KDM4E (1.00) | TDP1BLMKDM4EALDH1A1CYP1A2 | |
| Methyldopa SCHEMBL29352376 | 0.87 | KDM4E (1.00) | TDP1BLMKDM4EALDH1A1CYP1A2 | |
| Methyldopa SCHEMBL1172822 | 0.87 | KDM4E (1.00) | TDP1BLMKDM4EALDH1A1CYP1A2 | |
| Methyldopa SCHEMBL34003 | 0.87 | KDM4E (1.00) | TDP1BLMKDM4EALDH1A1CYP1A2 | |
| Methyldopa (Racemic) SCHEMBL196981 | 0.87 | KDM4E (1.00) | TDP1BLMKDM4EALDH1A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 188 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240350587-A1 | SYSTEMS AND METHODS FOR DELIVERY OF HUMANIN OR OTHER PEPTIDES | TRANSDERMAL BIOTECHNOLOGY, INC. (US) | 2024-10-24 | — | — | US | claimed |
| US-20240335409-A1 | SYSTEMS AND METHODS FOR DELIVERY OF PHENYLALANINE AND LACTATE | TRANSDERMAL BIOTECHNOLOGY, INC. (US) | 2024-10-10 | — | — | US | claimed |
| EP-4274838-B1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR NK CELLS | BICYCLETX LTD (GB) | 2024-09-25 | — | — | EP | claimed |
| US-12064467-B2 | Systems and methods for delivery of humanin or other peptides | TRANSDERMAL BIOTECHNOLOGY, INC. (US) | 2024-08-20 | — | — | US | claimed |
| US-20240158441-A1 | BRANCHED PEPTIDES FOR ENZYMATIC ASSEMBLY AND MITOCHONDRIA DRUG DELIVERY | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-05-16 | — | — | US | claimed |
| US-20240156900-A1 | SYSTEMS AND METHODS FOR DELIVERY OF HUMANIN OR OTHER PEPTIDES | TRANSDERMAL BIOTECHNOLOGY, INC. (US) | 2024-05-16 | — | — | US | claimed |
| US-11976280-B2 | SMAC/Diablo inhibitors useful for treating cancer | The National Institute for Biotechnology in the Negev Ltd. (IL) | 2024-05-07 | — | — | US | claimed |
| US-20240122884-A1 | SYSTEMS AND METHODS FOR DELIVERY OF N-LACTOYL-PHENYLALANINE AND OTHER N-LACTOYL-AMINO ACIDS | TRANSDERMAL BIOTECHNOLOGY, INC. (US) | 2024-04-18 | — | — | US | claimed |
| US-20240122888-A1 | SYSTEMS AND METHODS FOR DELIVERY OF PHENYLALANINE AND LACTATE | TRANSDERMAL BIOTECHNOLOGY, INC. (US) | 2024-04-18 | — | — | US | claimed |
| WO-2024076935-A1 | SYSTEMS AND METHODS FOR DELIVERY OF PHENYLALANINE AND LACTATE | TRANSDERMAL BIOTECHNOLOGY, INC. (US) | 2024-04-11 | — | — | WO | claimed |
| EP-2376101-A2 | ß-ARRESTIN EFFECTORS AND COMPOSITIONS AND METHODS OF USE THEREOF | Trevena, Inc. (US) | 2011-10-19 | — | — | EP | claimed |
| US-20100184701-A1 | Beta-Arrestin Effectors And Compositions And Methods Of Use Thereof | TREVENA, INC. | 2010-07-22 | — | — | US | claimed |
| WO-2010077339-A2 | β-ARRESTIN EFFECTORS AND COMPOSITIONS AND METHODS OF USE THEREOF | TREVENA, INC. (US) | 2010-07-08 | — | — | WO | claimed |
| US-20050080260-A1 | Preparation of prodrugs for selective drug delivery | LUMINIDE | 2005-04-14 | — | — | US | claimed |
| US-20040101523-A1 | Renal-selective prodrugs for control of renal smpathetic nerve activity in the treatment of hypertension | G.D. SEARLE & CO. | 2004-05-27 | — | — | US | claimed |
| US-20030220521-A1 | Renal-selective prodrugs for control of renal sympathetic nerve activity in the treatment of hypertension | G.D. SEARLE & CO. | 2003-11-27 | — | — | US | claimed |
| EP-0484437-A4 | RENAL-SELECTIVE PRODRUGS FOR THE TREATMENT OF HYPERTENSION | SEARLE & CO (US) | 1994-06-01 | — | — | EP | claimed |
| EP-0484437-A1 | RENAL-SELECTIVE PRODRUGS FOR THE TREATMENT OF HYPERTENSION | G.D. Searle & Co. (US) | 1992-05-13 | — | — | EP | claimed |
| WO-1992001667-A1 | RENAL-SELECTIVE PRODRUGS FOR CONTROL OF RENAL SYMPATHETIC NERVE ACTIVITY IN THE TREATMENT OF HYPERTENSION | G.D. SEARLE & CO. (US) | 1992-02-06 | — | — | WO | claimed |
| WO-1991001724-A1 | RENAL-SELECTIVE PRODRUGS FOR THE TREATMENT OF HYPERTENSION | G.D. SEARLE & CO. (US) | 1991-02-21 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050080260-A1 | Preparation of prodrugs for selective drug delivery | APEH, PAH, ALAD | TDP1 2098/4885BLM 2777/4885KDM4E 3072/4885 |
| US-20240350587-A1 | SYSTEMS AND METHODS FOR DELIVERY OF HUMANIN OR OTHER PEPTIDES | MTPN, NLN, MFN2 | TDP1 330/4885BLM 1694/4885KDM4E 3343/4885 |
| US-20240122884-A1 | SYSTEMS AND METHODS FOR DELIVERY OF N-LACTOYL-PHENYLALANINE AND OTHER N-LACTOYL-AMINO ACIDS | TYR, LANCL2, LRAT | TDP1 1619/4885BLM 4686/4885KDM4E 697/4885 |
| US-20240156900-A1 | SYSTEMS AND METHODS FOR DELIVERY OF HUMANIN OR OTHER PEPTIDES | MTPN, NLN, MFN2 | TDP1 330/4885BLM 1694/4885KDM4E 3343/4885 |
| US-20240122888-A1 | SYSTEMS AND METHODS FOR DELIVERY OF PHENYLALANINE AND LACTATE | TYR, LANCL2, LRAT | TDP1 1338/4885BLM 4573/4885KDM4E 718/4885 |
| US-20030220521-A1 | Renal-selective prodrugs for control of renal sympathetic nerve activity in the treatment of hypertension | GLS, APEH, GGH | TDP1 776/4885BLM 4877/4885KDM4E 1203/4885 |
| US-12064467-B2 | Systems and methods for delivery of humanin or other peptides | MTPN, NLN, MFN2 | TDP1 330/4885BLM 1694/4885KDM4E 3343/4885 |
| US-20100184701-A1 | Beta-Arrestin Effectors And Compositions And Methods Of Use Thereof | ARRB1, ADRB1, ADRB3 | TDP1 2200/4885BLM 2471/4885KDM4E 4734/4885 |
| US-20240335409-A1 | SYSTEMS AND METHODS FOR DELIVERY OF PHENYLALANINE AND LACTATE | TYR, LANCL2, LRAT | TDP1 1338/4885BLM 4573/4885KDM4E 718/4885 |
| US-20040101523-A1 | Renal-selective prodrugs for control of renal smpathetic nerve activity in the treatment of hypertension | GLS, DBH, APEH | TDP1 1535/4885BLM 4881/4885KDM4E 935/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.